This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GNFT GENFIT (GNFT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About GENFIT Stock (NASDAQ:GNFT) Get GENFIT alerts:Sign Up Key Stats Today's Range$4.85▼$4.8550-Day Range$3.86▼$4.8552-Week Range$3.41▼$4.93VolumeN/AAverage Volume7,393 shsMarket Capitalization$242.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Genfit is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies and diagnostics for serious metabolic and inflammatory liver diseases. Founded and headquartered in Lille, France, the company has concentrated its efforts on nonalcoholic steatohepatitis (NASH), an area of significant unmet medical need. By combining expertise in molecular biology, chemistry and medical imaging, Genfit aims to deliver products that can both treat disease and improve diagnosis and monitoring of liver conditions. The company’s lead therapeutic candidate, elafibranor (GFT505), is a first-in-class, dual PPAR alpha/delta agonist designed to address the underlying metabolic and inflammatory processes that drive NASH. Elafibranor has completed multiple Phase II and Phase III clinical studies assessing its efficacy and safety in patients with NASH, including those at risk for progression to fibrosis and cirrhosis. Genfit continues to explore additional indications and combination strategies to broaden the potential applicability of its pipeline assets. In parallel with its therapeutic programs, Genfit has developed proprietary diagnostic technologies to support the noninvasive assessment of liver health. Through a combination of imaging biomarkers and blood-based tests, the company seeks to provide physicians with tools for early detection, staging and monitoring of liver disease progression. Genfit’s diagnostics platform is designed to complement its drug development efforts and may be applied across diverse patient populations. Genfit operates in Europe and the United States, collaborating with clinical sites, academic institutions and industry partners to advance its research. The company is led by an experienced management team with backgrounds in biotechnology, pharmaceutical development and medical research. Genfit continues to pursue regulatory interactions and strategic collaborations to bring its therapies and diagnostics to patients worldwide.AI Generated. May Contain Errors. Read More Receive GNFT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GENFIT and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNFT Stock News HeadlinesGENFIT Advances Nangibotide In Acute-on-Chronic Liver Failure, Mid-Stage Data Expected In 2027November 9, 2026 | rttnews.comGENFIT Reports Third Quarter 2026 Financial Information and Provides Corporate UpdateNovember 5, 2026 | markets.businessinsider.comELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.November 20 at 1:00 AM | Paradigm Press (Ad)GENFIT to Highlight Progress in ACLF and MASH Diagnostics at AASLD The Liver Meeting® 2026November 2, 2026 | finance.yahoo.comGENFIT Reports First-Half 2026 Financial Results and Provides Corporate UpdateSeptember 28, 2026 | markets.businessinsider.comGENFIT S.A.: GENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLFSeptember 15, 2026 | finanznachrichten.deGENFIT Advances Nangibotide in Phase 2 Clinical Investigation in ACLFSeptember 14, 2026 | finance.yahoo.comGENFIT to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 10, 2026 | markets.businessinsider.comSee More Headlines GNFT Stock Analysis - Frequently Asked Questions When did GENFIT IPO? GENFIT (GNFT) raised $125 million in an IPO on Wednesday, March 27th 2019. The company issued 6,150,000 shares at a price of $20.32 per share. SVB Leerink and Barclays served as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers. What other stocks do shareholders of GENFIT own? Based on aggregate information from My MarketBeat watchlists, some other companies that GENFIT investors own include Intercept Pharmaceuticals (ICPT), Tesla (TSLA), Viking Therapeutics (VKTX), ChargePoint (CHPT), ADMA Biologics (ADMA), Blink Charging (BLNK) and Corbus Pharmaceuticals (CRBP). Company Calendar Today11/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GNFT CIK1757064 Webwww.genfit.com Phone(332) 016-4000FaxN/AEmployees120Year Founded1999Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.09 Current Ratio3.74 Quick Ratio3.74 Sales & Book Value Annual Sales$41.52 million Price / Sales5.84 Cash Flow$0.07 per share Price / Cash Flow69.34 Book Value$1.50 per share Price / Book3.23Miscellaneous Outstanding Shares50,025,000Free Float47,924,000Market Cap$242.62 million OptionableNot Optionable Beta1.09 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:GNFT) was last updated on 4/8/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENFIT S.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share GENFIT With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.